Fighting fire with fire: Attacking the complexity of human tumors with armed therapeutic viruses

Current Opinion in Molecular Therapeutics

Volumn 4, Issue 4, 2002, Pages 334-342

  Hermiston, Terry ^a  

^a BAYER AG   (Germany)

Author keywords

Armed therapeutic virus; Cancer; Gene expression; Gene therapy; Hypoxia; Immunotherapy; Oncolytic virus

Indexed keywords

ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CD8 ANTIGEN; GLYCOPROTEIN GP 100; IMATINIB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; MONOPHENOL MONOOXYGENASE; ONCOLYTIC VIRUS; PROTEIN P53; RAS PROTEIN; VIRUS ANTIGEN;

CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; CLONAL VARIATION; GENE EXPRESSION; GENE TARGETING; HUMAN; NONHUMAN; ONCOGENE NEU; ONCOGENE RAS; PROMOTER REGION; REVIEW; SOLID TUMOR; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION;

GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; PROMOTER REGIONS (GENETICS); SELECTION (GENETICS); VIRUSES;

EID: 0036705516     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell (2000) 100:57-70.
2. Roth JA, Cristiano RJ: Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst (1997) 89:21-39.
3. Wasil T, Buchbinder A: Gene therapy in human cancer: Report of human clinical trials. Cancer Invest (2000) 18:740-746.
4. Anklesaria P: Gene therapy: A molecular approach to cancer treatment. Curr Opin Mol Ther (2000) 2:426-432.
5. McCormick F: Cancer gene therapy: Fringe or cutting edge? Nat Rev Cancer (2001) 1:130-141.
6. Nowell PC: The clonal evolution of tumor cell populations. Science (1976) 194:23-28.
7. Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, Chen L, Smith HS, Pinkel D, Gray JW, Waldman FM: Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA (1994) 91:2156-2160.
8. Iwabuchi H, Sakamoto M, Sakunaga H, Ma Y-Y, Carcangiu ML, Pinkel D, Yang-Feng TL, Gray JW: Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res (1995) 55:6172-6180.
9. Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature (1998) 396:643-649.
10. Jackson AL, Loeb LA: On the origin of multiple mutations in human cancers. Semin Cancer Biol (1998) 8:421-429.
11. Stoler DL, Chen N, Basik M, Kahlenberg MS, Rodriguez-Bigas MA, Petrelli NF, Anderson GR: The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc Natl Acad Sci USA (1999) 96:15121-15126.
12. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C: Genetic instability and Darwinian selection in tumours. Trends Cell Biol (1999) 9:M57-M60.
13. Loeb LA: Mutator phenotype may be required for multistage carcinogenesis. Cancer Res (1991) 51:3075-3079.
14. Pihan GA, Doxsey SJ: The mitotic machinery as a source of genetic instability in cancer. Semin Cancer Biol (1999) 9:289-302.
15. Sen S: Aneuploidy and cancer. Curr Opin Oncol (2000) 12:82-88.
16. Thiagalingam S, Foy RL, Cheng KH, Lee HJ, Thiagalingam A, Ponte JF: Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer: Molecular basis of its occurrence. Curr Opin Oncol (2002) 14:65-72.
17. Huang J, Papadopoulos N, McKinley AJ, Farrington SM, Curtis LJ, Wyllie AH, Zheng S, Willson JKV, Markowitz SD, Morin P, Kinzler KW et al: APC mutations in colorectal tumors with mismatch repair deficiency. Proc Natl Acad Sci USA (1996) 93:9049-9054.
18. Galipeau PC, Prevo LJ, Sanchez CA, Longton GM, Reid BJ: Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst (1999) 91:2087-2095.
19. Willenbucher RF, Aust DE, Chang CG, Zelman SJ, Ferrell LD, Moore DH, Waldman FM: Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am J Pathol (1999) 154:1825-1830.
20. Washington C, Dalbegue F, Abreo F, Taubenberger JK, Lichy JH: Loss of heterozygosity in fibrocystic change of the breast: Genetic relationship between benign proliferative lesions and associated carcinomas. Am J Pathol (2000) 157:323-329.
21. Pinto AP, Lin MC, Sheets EE, Muto MG, Sun D, Crum CP: Allelic imbalance in lichen sclerosus, hyperplasia, and intraepithelial neoplasia of the vulva. Gynecol Oncol (2000) 77:171-176.
22. Kobayashi K, Okamoto T, Takayama S, Akiyama M, Ohno T, Yamada H: Genetic instability in intestinal metaplasia is a frequent event leading to well-differentiated early adenocarcinoma of the stomach. Eur J Cancer (2000) 36:1113-1119.
23. Shen C-Y, Yu J-C, Lo Y-L, Kuo C-H, Yue C-T, Jou Y-S, Huang C-S, Lung J-C, Wu C-W: Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: An implication for mutator phenotype and breast cancer pathogenesis. Cancer Res (2000) 60:3884-3892.
24. Shih I-M, Zhou M, Goodman SN, Lengauer C, Kinzler KW, Vogelstein B: Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Res (2001) 61:818-822.
25. Hockel M, Vaupel P: Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl. Cancer Inst (2001) 93:266-276.
26. Harris AL: Hypoxia - A key regulatory factor in tumour growth. Nat Rev Cancer (2002) 2:38-47.
27. Stoler DL, Anderson GR, Russo CA, Spina AM, Beerman TA: Anoxia-inducible endonuclease activity as a potential basis of the genomic instability of cancer cells. Cancer Res (1992) 52:4372-4378.
28. Russo CA, Weber TK, Volpe CM, Stoler DL, Petrelli NJ, Rodriguez-Bigas M, Burhans WC, Anderson GR: An anoxia inducible endonuclease and enhanced DNA breakage as contributors to genomic instability in cancer. Cancer Res (1995) 55:1122-1128.
29. Coquelle A, Toledo F, Stern S, Bieth A, Debatisse M: A new role for hypoxia in tumor progression: Induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol Cell (1998) 2:259-265.
30. Yuan J, Narayanan L, Rockwell S, Glazer PM: Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res (2000) 60:4372-4376.
31. Gray LH, Coger AD, Ebert M, Hornsey S, Scott OC: The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol (1953) 26:638-648.
32. Tannock IF: Tumor physiology and drug resistance. Cancer Metastasis Rev (2001) 20:123-132.
33. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S: Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2002) 20:621-667.
34. Berke G: The CTL's kiss of death. Cell (1995) 81:9-12.
35. Perales M-A, Blachere NE, Engelhorn ME, Ferrone CR, Gold JS, Gregor PD, Noffz G, Wolchok JD, Houghton AN: Strategies to overcome immune ignorance and tolerance. Semin Cancer Biol (2002) 12:63-71.
36. Jager E, Jager D, Knuth A: Clinical cancer vaccine trials. Curr Opin Immunol (2002) 14:178-182.
37. Vicari AP, Caux C, Trinchieri G: Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol (2002) 12:33-42.
38. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F: The Fas counterattack: Cancer as a site of immune privilege. Immunol Today (1999) 20:46-52.
39. Drake CG, Pardoll DM: Tumor immunology - Towards a paradigm of reciprocal research. Semin Cancer Biol (2002) 12:73-80.
40. Pardoll DM: Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol (2002) 2:227-238.
41. Dranoff G: Immune recognition and tumor protection. Curr Opin Immunol (2002) 14:161-164.
42. Paget S: The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev (1999) 8:98-101.
43. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL et al: Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 410:50-56.
44. O'Dwyer ME, Druker BJ: STI571: An inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. Lancet Oncol (2000) 1:207-211.
45. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 293:876-880.
46. Galanis E, Russell S: Cancer gene therapy clinical trials: Lessons for the future. Br J Cancer (2001) 85:1432-1436.
47. Webb HE, Smith CEG: Viruses in the treatment of cancer. Lancet (1970) 1:1206-1208.
48. Wickham TJ: Targeting adenovirus. Gene Ther (2000) 7:110-114.
49. Galanis E, Vile R, Russell SJ: Delivery systems intended for in vivo gene therapy of cancer: Targeting and replication competent viral vectors. Crit Rev Oncol Hematol (2001) 38:177-192.
50. Romanczuk H, Galer CE, Zabner J, Barsomian G, Wadsworth SC, O'Riordan CR: Modification of an adenoviral vector with biologically selected peptides: A novel strategy for gene delivery to cells of choice. Hum Gene Ther (1999) 10:2615-2626.
51. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW: Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther (2001) 8:341-348.
52. Chester J, Ruchatz A, Gough M, Crittenden M, Chong H, Loic-Cosset F, Diaz RM, Harrington K, Alvarez-Vallina L, Vile R: Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nat Biotechnol (2002) 20:256-263.
53. Kirn DL: Replication-selective microbiological agents: Fighting cancer with targeted germ warfare. J Clin Invest (2000) 105:847-851.
54. Kirn D, Martuza RL, Zwiebel J: Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med (2001) 7:781-787.
55. Hawkins LK, Lemoine NR, Kirn D: Oncolytic biotherapy: A novel therapeutic platform. Lancet Oncol (2002) 3:17-26.
56. Wildner O: Oncolytic viruses as therapeutic agents. Ann Med (2001) 33:291-304.
57. Ring CJA: Cytolytic viruses as potential anti-cancer agents. J Gen Virol (2002) 83:491-502.
58. Kruyt FAE, Curiel DT: Toward a new generation of conditionally replicating adenoviruses: Pairing tumor selectivity with maximal oncolysis. Hum Gene Ther (2002) 13:485-495.
59. Liotta LA, Kohn EC: The microenvironment of the tumour-host interface. Nature (2001) 411:375-379.
60. Bissell MJ, Radisky D: Putting tumours in context. Nat Rev Cancer (2001) 1:46-54.
61. Hermiston T: Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer. J Clin Invest (2000) 105:1169-1172.
62. Bett AJ, Prevec L, Graham FL: Packaging capacity and stability of human adenovirus type 5 vectors. J Virol (1993) 67:5911-5921.
63. Martinez-Salas E: Internal ribosome entry site biology and its use in expression vectors. Curr Opin Biotechnol (1999) 10:458-464.
64. Vagner S, Galy B, Pyronnet S: Irresistible IRES. Attracting the translation machinery to internal ribosome entry sites. EMBO Rep (2001) 2:893-898.
65. DeFelipe P, Izquierdo M: Tricistronic and tetracistronic retroviral vectors for gene transfer. Hum Gene Ther (2000) 11:1921-1931.
66. Hamstra DA, Rehemtulla A: Toward an enzyme/prodrug strategy for cancer gene therapy: Endogenous activation of carboxypeptidase A mutants by the PACE/furin family of propeptidases. Hum Gene Ther (1999) 10:235-248.
67. Hawkins LK, Johnson L, Bauzon M, Nye JA, Castro D, Kitzes GA, Young GA, Young MD, Holt JK, Trown P, Hermiston TW: Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the 6.7K/gp19K region. Gene Ther (2001) 8:1123-1131.
68. Hawkins LK, Hermiston TW: Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the ADP region. Gene Ther (2001) 8:1132-1141.
69. Hawkins LK, Hermiston TW: Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the E3B region. Gene Ther (2001) 8:1142-1148.
70. Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P, Petersson M: Tumor-induced immune dysfunction. Cancer Immunol Immunother (1999) 48:353-362.
71. Li E, Stupack D, Bokoch GM, Nemerow GR: Adenovirus endocytosis requires actin cytoskeleton reorganization mediated by Rho family GTPases. J Virol (1998) 72:8806-8812.
72. Roymans D, Slegers H: Phosphatidylinositol 3-kinases in tumor progression. Eur J Biochem (2001) 268:487-498.
73. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield, MD: Cellular function of phosphoinositide 3-kinases: Implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol (2001) 17:615-675.
74. Berrie CP: Phosphoinositide 3-kinase inhibition treatment in cancer treatment. Exp Opin Invest Drugs (2001) 10:1085-1098.
75. Heise C, Sampson-Johannes A, Williams A, McCormick F, von Hoff DD, Kirn DH: ONYX-015, an E1B gene-attenuated adenovirus, causes tumour-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med (1997) 3:639-645.
76. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH: A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther (1998) 9:1323-1333.
77. Chahlavi A, Todo T, Martuza RL, Rabkin SD: Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia (1999) 1:162-169.
78. Spear MA, Sun F, Eling DJ, Gilpin E, Kipps TJ, Chiocca EA, Bouvet M: Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Ther (2000) 7:1051-1059.
79. Rogulski KR, Wing MS, Paielli DL, Gilbert JD, Kim JH, Freytag SO: Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum Gene Ther (2000) 11:67-76.
80. Rogulski KR, Freytag SO, Zhang K, Gilbert JD, Paielli DL, Kim JH, Heise CC, Kirn DH: In vivo antitumor activity of ONYX-015 is influence by p53 status and is augmented by radiotherapy. Cancer Res (2000) 60:1193-1196.
81. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B et al: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 6:879-885.
82. Jorgensen TJ, Katz S, Wittmack EK, Varghese S, Todo T, Rabkin SD, Martuza RL: Ionizing radiation does not alter the antitumor activity of herpes simples virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia (2001) 3:451-456.
83. Kirn D: Clinical research results with dl1520 (ONYX-015), a replication-selective adenovirus for the treatment of cancer: What have we learned? Gene Ther (2001) 8:89-98.